Skip to main content
. 2021 Dec 1;13(23):6050. doi: 10.3390/cancers13236050
AUC area under the receiver operating characteristic curve
DR dissociated response
GEE generalized estimating equation
HPD hyperprogressive disease
ICI immune checkpoint inhibitor
iRECIST modified RECIST 1.1 for immune-based therapeutics
irRC immune-related response criteria
irRECIST immune-related RECIST
NSCLC non-small cell lung cancer
OS overall survival
PD progressive disease
PD-1 receptor programmed cell death 1
PD-L1 programmed death ligand 1
PR partial response
ROC receiver operating characteristic
SD stable disease
TGK tumor growth kinetics